ICOS (CD278)

Target id: 2939

Nomenclature: ICOS (CD278)

Family: Other immune checkpoint proteins, CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     ICOS (CD278) has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 199 2q33.2 ICOS inducible T-cell costimulator 1
Mouse 1 200 1 C2; 1 30.6 cM Icos inducible T cell co-stimulator
Rat 1 200 9q32 Icos inducible T-cell co-stimulator
Previous and Unofficial Names
activation-inducible lymphocyte immunomediatory molecule | AILIM | CVID1
Database Links
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands
ICOS ligand {Sp: Human}
Immunopharmacology Comments
Inducible T cell costimulator (ICOS) and it's ligand constitute an immune checkpoint. ICOS is a surface receptor on activated T cells that binds its ligand on antigen presenting cells. Ligand-receptor interaction is a T cell activation signal. ICOS is major regulator of the adaptive immune reponse that is structurally and functionally related to CD28 [1]. ICOS is being investigated as an immuno-oncology drug target. Agonist-like binding of anti-ICOS monoclonal antibodies (mAbs) to ICOS expressed on tumour infiltrating CD4-positive T cells stimulates ICOS-positive T cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumour cells. Anti-ICOS mAbs such as JTX-2011 and GSK3359609 are being evaluated in early stage clinical trials as either monotherapy or in combination with other immune checkpoint inhibitor mAbs vs. various solid tumour types (JTX-2011: Phase 1/2 NCT02904226 ±anti-PD-1 checkpoint inhihbitor nivolumab; GSK3359609: Phase 1 NCT02723955 ±anti-PD-1 checkpoint inhihbitor pembrolizumab).
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Immuno Process ID:  9
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  interleukin-7-mediated signaling pathway (GO:0038111) TAS
References: 
Immuno Process:  T cell (activation)
Immuno Process ID:  4
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  T cell costimulation (GO:0031295) TAS
References: 
Immuno Process:  Immune regulation
Immuno Process ID:  6
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  T cell costimulation (GO:0031295) TAS
References: 
Immuno Process:  Chemotaxis & migration
Immuno Process ID:  10
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  T cell costimulation (GO:0031295) TAS
References: 
Immuno Process:  Cellular signalling
Immuno Process ID:  11
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  T cell costimulation (GO:0031295) TAS
References: 
Immuno Process:  Immune system development
Immuno Process ID:  8
Comment: 
GO Annotation:  Associated to GO processes, IEA only
GO Processes:  T cell tolerance induction (GO:0002517) IEA
References: 
General Comments
ICOS belongs to the CD28 and CTLA-4 cell-surface receptor family. It is active as homodimers and is a costimulatory molecule involved in cell-cell signaling, innate immune responses, and regulation of cell proliferation.

References

Show »

1. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. (1999) ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature397 (6716): 263-6. [PMID:9930702]

How to cite this page

Other immune checkpoint proteins: ICOS (CD278). Last modified on 07/06/2017. Accessed on 17/12/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2939.